CTI BioPharma (NASDAQ:CTIC) Issues Earnings Results

CTI BioPharma (NASDAQ:CTIC) released its earnings results on Thursday. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.19), Bloomberg Earnings reports. The company had revenue of $0.42 million for the quarter. CTI BioPharma had a negative net margin of 224.53% and a negative return on equity of 67.97%.

CTI BioPharma stock traded down $0.05 during mid-day trading on Friday, reaching $0.69. 364,463 shares of the company’s stock were exchanged, compared to its average volume of 146,326. CTI BioPharma has a twelve month low of $0.60 and a twelve month high of $2.34. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.18. The stock’s fifty day simple moving average is $0.83.

About CTI BioPharma

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Read More: What is the NASDAQ?

Earnings History for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.